/

SPRO

Spero Therapeutics, Inc.Closed

1.15−0.03 −2.54%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delay

Open

1.19

Prev close

1.18

Day range

1.151.20

52-week range

1.083.08

Volume

272.49K0.26×

Mkt cap

66.97M

P/E ttm

8.21

Fwd P/E

-1.04

EPS ttm

0.1400

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−62.66%

Price Chart

Yahoo Finance · delayed

SPROOct 13, 2026O 1.19H 1.20L 1.15C 1.15−0.03 (−2.54%)Vol 272.50K

SMA 501.20
SMA 2002.07

1Y change −49.78% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SPRO Spero Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.36%
1 month: +1.77%
3 months: −32.35%
6 months: −58.63%
Year to date: −50.64%
1 year: −49.78%

Valuation & ownership

Market cap: 66.97M
Enterprise value: 18.24M
P/E (ttm): 8.21
Forward P/E: -1.04
PEG ratio: —
Price / book: 1.51
Price / sales (ttm): 1.42
EV / EBITDA: —
EPS (ttm): 0.1400
EPS (forward): -1.11
Beta (5y monthly): 1.50
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 58.23M
Float: 47.10M
Short % of float: 1.64%
Short ratio (days): 1.06
Held by insiders: 22.66%
Held by institutions: 18.25%
Avg volume (3m): 1.04M
50-day average: 1.20
200-day average: 2.07
52-week change: −49.78%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 44.5
vs 50-day SMA: −4.25%
vs 200-day SMA: −44.39%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.17%
Realised vol (20d, ann.): 81.3%
From 52-week high: −62.66%
From 52-week low: +6.48%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

5.00

+334.78% implied

Low 4.00Median 5.00High 6.00

Recommendation trend

Now1 / 1 / 0

Buy / hold / sell counts

Recent actionsAll (UPDN) →

Sep 14HC Wainwright & Co. · Buy

DES

About Spero Therapeutics, Inc.

Yahoo Finance profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 25
Headquarters: Cambridge, MA, United States
Website: sperotherapeutics.com
Officers: Ms. Esther P. Rajavelu CEO, President, CFO, Chief Business Officer, Treasurer & Director
Mr. Timothy Keutzer Chief Operating Officer
Mr. John Raymond Senior Vice President of Finance & Business Operations
Dr. Debra Jeske Zack M.D., Ph.D.

SEAS

Seasonality · SPRO

2017–2026 · monthly returns

Strongest month May +23.95%Weakest month Jul −6.19%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-6.0	-0.9	7.8	7.3	12.7	-21.9	-47.1	4.3	-0.8	-5.0			−50.6%
2025	-16.8	-9.5	-7.2	-8.6	279.9	16.0	-20.0	-10.8	-9.2	29.3	-1.2	-2.9	+126.2%
2024	3.4	8.6	4.2	-17.4	0.0	-8.5	8.5	-2.8	-2.2	-8.2	-7.3	-9.6	−29.9%
2023	6.9	-20.0	-2.0	22.1	-1.7	-16.7	12.4	-8.0	-19.3	-10.7	5.6	28.9	−15.0%
2022	-25.9	-19.1	-9.4	-44.1	-75.7	-37.2	-1.2	10.2	147.8	-2.0	-1.0	-10.8	−89.2%
2021	-6.6	0.3	-19.0	-6.5	5.4	-3.7	-4.4	44.3	-4.4	-4.6	-18.8	12.4	−17.4%
2020	-4.2	3.6	-15.3	53.8	-4.9	14.5	-13.5	-7.1	2.7	17.5	26.4	17.0	+101.7%
2019	71.1	12.2	8.6	-12.7	0.7	2.2	-9.7	-4.2	6.5	3.5	9.0	-19.6	+56.3%
2018	3.0	-12.6	34.7	-15.0	-12.1	37.9	-21.5	-1.0	-7.9	-23.7	2.0	-24.8	−47.7%
2017												-1.7	−1.7%

INSD

Insider Activity · SPRO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

232.3K shares

Sells, 6 months

25.2K shares

Net shares

+207.1K

Net change in insider shares

+1.60%

Date	Insider	Transaction	Shares	Value
Aug 2, 2026	Zack Debra JeskeOfficer	Stock Award(Grant) at price 0.00 per share.	162.3K	—
Jun 22, 2026	Smith CynthiaDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 22, 2026	Thomas Frank EDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 22, 2026	Deshpande Milind SDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 22, 2026	Pottage John C JrDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 22, 2026	Vink Patrick V.J.J M.D.Director	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 22, 2026	Jackson Scott ThomasDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
Jun 22, 2026	Tregoning KathleenDirector	Stock Award(Grant) at price 0.00 per share.	10K	—
May 3, 2026	Rajavelu EstherChief Executive Officer	Sale at price 2.51 per share.	25.2K	$63.35K
Feb 5, 2026	Keutzer TimothyChief Operating Officer	Sale at price 2.36 per share.	18.7K	$44.02K
Feb 5, 2026	Rajavelu EstherChief Executive Officer	Sale at price 2.36 per share.	87.9K	$207.48K
Feb 3, 2026	Keutzer TimothyChief Operating Officer	Sale at price 2.14 - 2.24 per share.	46.6K	$101.17K
Feb 1, 2026	Rajavelu EstherChief Executive Officer	Sale at price 2.20 per share.	18.4K	$40.57K
Feb 1, 2026	Keutzer TimothyChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	68K	—
Feb 1, 2026	Rajavelu EstherChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	249K	—
Nov 6, 2025	Rajavelu EstherChief Executive Officer	Sale at price 2.37 per share.	40.3K	$95.44K
Aug 27, 2025	Mahadevia AnkitDirector	Sale at price 1.97 per share.	6.6K	$12.95K
Aug 27, 2025	Keutzer TimothyChief Operating Officer	Sale at price 1.97 per share.	1.7K	$3.34K
Jun 11, 2025	Smith CynthiaDirector	Stock Award(Grant) at price 0.00 per share.	20K	—
Jun 11, 2025	Thomas Frank EDirector	Stock Award(Grant) at price 0.00 per share.	20K	—

13F

Investors Holding SPRO

latest 13F filings of 29 followed managers

Investors holding SPRO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$2.1M	0.00%	947.90K	−20%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

SPRO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SPRO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Spero Therapeutics, Inc.

Seasonality · SPRO

Insider Activity · SPRO

Congress Trades · SPRO

Investors Holding SPRO

Investors Holding SPRO

Congress Trades · SPRO

Insider Activity · SPRO

Seasonality · SPRO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Spero Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News